Comparison of real-world data (rwd) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with pd-l1 < 50%

HIGHLIGHTS

• who: Ilaria Attili from the University of Naples Federico II, Italy have published the research: Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%, in the Journal: (JOURNAL) of 10/04/2022
• what: The real -world study aimed at assessing whether the possibility to sequence chemotherapy and immunotherapy would be beneficial instead of the standard chemo-immunotherapy approach, focusing on the subgroup of patients with non-squamous histology and PDL1 and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.